600 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Glenview State Bank Trust DEPT.

Glenview State Bank Trust DEPT. bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 600 shares of the life sciences company’s stock, valued at approximately $221,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in Illumina by 2.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 256,825 shares of the life sciences company’s stock valued at $77,031,000 after acquiring an additional 5,007 shares during the period. Geode Capital Management LLC boosted its holdings in Illumina by 10.1% during the fourth quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after acquiring an additional 170,046 shares during the period. Financial Advocates Investment Management boosted its holdings in Illumina by 1,430.0% during the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 572 shares during the period. TrimTabs Asset Management LLC boosted its holdings in Illumina by 5.0% during the first quarter. TrimTabs Asset Management LLC now owns 5,578 shares of the life sciences company’s stock valued at $1,733,000 after acquiring an additional 266 shares during the period. Finally, Hudson Valley Investment Advisors Inc. ADV boosted its holdings in Illumina by 4.9% during the first quarter. Hudson Valley Investment Advisors Inc. ADV now owns 12,812 shares of the life sciences company’s stock valued at $3,981,000 after acquiring an additional 600 shares during the period. 90.75% of the stock is currently owned by institutional investors.

In related news, SVP Charles Dadswell sold 124 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $300.00, for a total value of $37,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Francis A. Desouza sold 3,000 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $301.25, for a total transaction of $903,750.00. Following the completion of the transaction, the chief executive officer now directly owns 64,200 shares of the company’s stock, valued at approximately $19,340,250. The disclosure for this sale can be found here. Insiders have sold 60,991 shares of company stock valued at $19,789,080 in the last ninety days. 0.38% of the stock is owned by company insiders.

Shares of ILMN opened at $291.94 on Wednesday. The company’s 50-day moving average is $331.46. The firm has a market capitalization of $43.71 billion, a price-to-earnings ratio of 51.04, a P/E/G ratio of 2.77 and a beta of 1.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.79 and a quick ratio of 6.10. Illumina, Inc. has a 52 week low of $268.62 and a 52 week high of $380.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.43 earnings per share. Equities research analysts predict that Illumina, Inc. will post 6.04 earnings per share for the current year.

A number of equities research analysts have issued reports on ILMN shares. Wolfe Research started coverage on shares of Illumina in a report on Thursday, May 30th. They set an “outperform” rating for the company. Argus decreased their price target on shares of Illumina to $340.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Cowen decreased their price target on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, July 12th. Bank of America lowered shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price objective for the company. in a research report on Friday, July 12th. Finally, Piper Jaffray Companies cut their price objective on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $330.92.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Beige Book

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.